SCS Capital Management’s Vir Biotechnology VIR Stock Holding History

SCS Capital Management’s Portfolio VIR Stock Details VIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$247K	Hold	24,200	–	–	﹤0.01%	440
2026 Q1	$217K	Hold	24,200	–	–	﹤0.01%	444
2025 Q4	$146K	Hold	24,200	–	–	﹤0.01%	482
2025 Q3	$138K	Hold	24,200	–	–	﹤0.01%	500
2025 Q2	$122K	Hold	24,200	–	–	﹤0.01%	537
2025 Q1	$157K	Buy	+24,200	New	+$215K	﹤0.01%	496

Other funds holding VIR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GSK plc London $602M AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

SCS Capital Management's VIR Position: Q2 2026 in Review

SCS Capital Management held its Vir Biotechnology (VIR) position steady in Q2 2026 at 24,200 shares worth $247K. The position accounts for ﹤0.01% of the portfolio, ranked #440.

SCS Capital Management first reported a position in VIR in Q1 2025 and has held it in 6 quarters since. 237 funds tracked by Wall St. Rank hold VIR as of Q2 2026.

SCS Capital Management held 24,200 shares of Vir Biotechnology worth $247K as of Q2 2026.
SCS Capital Management left its Vir Biotechnology share count unchanged in Q2 2026.
Vir Biotechnology made up ﹤0.01% of SCS Capital Management's portfolio in Q2 2026, its #440 holding.
SCS Capital Management first reported a position in Vir Biotechnology in Q1 2025 and has held it in 6 quarters since.
237 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2026.

Based on SCS Capital Management's 13F filing for Q2 2026, filed 6 Aug 2026.